Pattern of systemic lupus erythematosus in Egyptian patients: the impact of disease activity on the quality of life by Nagwa Ibrahim et al.
Page number not for citation purposes  1 
 
 
 
 
Pattern of systemic lupus erythematosus in Egyptian patients:  the impact of disease 
activity on the quality of life  
 
Hamdy Sliem
1,&, Gamal Tawfik
1, Khalil A Khalil
1, Nagwa Ibrahim
1 
 
1Department of Internal Medicine, Faculty of Medicine, Suez Canal University, Egypt 
 
&Corresponding author: Department of internal medicine, Faculty of Medicine, Suez Canal University, Ismailia, Post-code 41522. Tel: 002-064-
2381410, Egypt. 
 
Key words: Systemic lupus erythematosus, SLE, quality of life, SLE Disease Activity Index, Short Form–36 health questionnaire 
 
Received: 18/08/2010 - Accepted: 23/08/2010 - Published: 29/08/2010 
 
Abstract 
Introduction: Systemic lupus erythematosus (SLE) afflicts young people disproportionately, often at a crucial time in their lives when they are 
trying to establish relationships, start families and launch careers. As a result, persons with SLE may experience a wide range of physical and 
psychosocial problems that are not always fully captured by descriptions of the disease’s physiological consequences alone. Methods: In order to 
characterize the spectrum of the effects of SLE with regards to disease activity and its impact on the quality of life (QoL), a case control study 
involving 59 SLE Egyptian patients (mean age 28.6 years, 94.9% females) and 20 healthy controls was undertaken. Disease activity was measured 
by  SLE  Disease  Activity  Index  (SLEDAI),  and  quality  of  life  was  measured  by  Short  Form–36  health  questionnaire  (SF-36).  Results: 
Mucocutaneous and hematological manifestations were present in most of the patients and arthralgia in half of them. All domains of SF-36 
including general health, physical functions, physical limitations, energy/fatigue, emotional well-being, pain, social functions, and health changes 
were significantly lower in SLE patients compared to controls.  Except for emotional limitations, all domains were correlated with disease activity 
and low in class IV-V lupus nephritis. Conclusion: Physicians should focus on QoL and how to improve it; health education regarding the negative 
impact of disease activity on the patients should be given attention. The results of QoL studies help physicians to understand and provide better 
support to SLE patients beside rapid meticulous control of disease activity. 
 
 
Pan African Medical Journal. 2011; 6:14  
This article is available online at: http://www.panafrican-med-journal.com/content/article/6/14/full/ 
 
© Hamdy Sliem et al.   The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the 
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction 
in any medium, provided the original work is properly cited. 
 
 
 
 
 
Pan Africa Medical Journal – ISSN: 1937- 8688   (www.panafrican-med-journal.com) 
Published in partnership with the African Field Epidemiology Network (AFENET). (www.afenet.net) 
 
Research  
Open Access 
 Page number not for citation purposes  2 
Introduction 
 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting almost all organ systems. It is characterized by exacerbations (or 
flares) of disease activity and disease damages. Measures of disease activity include; SLE disease activity index (SLEDAI) [1], British Isles Lupus 
Assessment Group (BILAG) disease activity index [2] and SLE Activity Measure (SLAM) [3]. 
  
However, in addition to disease activity and damages, other important consequences of the disease include changes in Quality of Life (QoL) 
affecting  employment  and  social  functioning.  Therefore,  in  an  effort  to  improve  assessment  of  outcomes  in  SLE,  the  outcome  measures  in 
rheumatology clinical trials group has recommended that trials of SLE include outcome measures of QoL, adverse events and economic costs, in 
addition to measures of disease activity and damages [4]. 
  
The term health related QoL (HRQoL) refers to those aspects of life which are affected by health e.g. functional status, and excludes other 
determinants of QoL e.g.: income, job security or living conditions [5]. Measuring of HRQoL provides patients with an opportunity to participate 
more fully in their treatment and ultimately facilitate better communication with the multi-disciplinary team of health professionals involved in their 
care [6]. In addition to more objective clinical indicators of disease, measurement of HRQoL, allows for a more comprehensive assessment and in 
some cases may prove to be a more sensitive indicator of treatment response than measures of disease activity or damages [4,5]. 
  
The most commonly used measure of HRQoL is the short form (SF)-36. The SF-36 is a generic, 36-item self-report questionnaire. It was designed 
to be used in a variety of conditions, populations, and settings. The SF-36 has been shown to be a valid and reliable instrument in SLE and has 
been used in numerous studies in SLE [7]. 
  
In order to evaluate QoL in rural and urban areas in Lebanon, the SF-36 health survey was adapted into Arabic [8]. In Egypt, reliability of an 
Arabic version of the SF 36-Item health survey and its equivalence to the US-English version was performed by Abdul-Mohsin et al. [9].  
  
On the basis of the hypothesis (SLE is a disease characterized by a variety of clinical manifestation with changes of its activity over time, and the 
quality of life of SLE patients during disease activity is low), the present study was designed with four objectives: 1) Studying the clinical and 
biochemical pattern of SLE in Egyptian patients; 2) Assess different aspects of quality of life in terms of physical, mental, psychological and social 
aspects; 3) Assess disease activity using SLEDI score; 4) Assess factors affecting quality of life including disease activity and renal involvement that 
were confirmed by previous records of kidney pathology. 
 
 
Methods 
 
The present study was conducted as a descriptive case control study on 59 of SLE patients who registered at SLE special outpatient clinic in the 
Suez Canal University Hospital from January 2008 to April 2009. All fulfilled the Criteria of Classification of the American College of Rheumatology 
(ACR) for diagnosis of SLE [10] 
  
Twenty healthy adults matched for age and gender were considered as a control group. They were defined by self-report and confirmed by 
physician observations. The control group was added to be compared with SLE group regarding QoL assessment. 
  
The sample size was calculated according to the following equation [11]: N=(Za) 2 X PQ/D2: Where: N= number of subjects. Za = the value of 
standard normal distribution for type I error probability for the sided test and equals 1.96; P=prevalence of poor QoL of SLE patients=81%. Q=1-
P, D2=the accuracy of estimate= 0.01. According to the calculations, the sample size was estimated at 59 patients. 
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At the time of HRQoL assessment, all patients were subjected to the following: 1) Complete medical history and clinical examination, 2) Outcome 
measures and assessment questionnaires: Disease activity was measured by SLEDAI score and measure of QoL was done by Medical Outcomes 
Study SF-36, which is a generic measure that is applicable in a variety of conditions, including SLE. 
  
Measuring disease activity using SLEDAI 
  
SLEDAI has 24 descriptors representing 9 organ systems affected by SLE. For every organ, score points are calculated. Points are based on a 
"weighted" index for lupus disease activity with 8 points for central nervous system and vascular system; 4 points for renal and musculoskeletal 
systems; 2 points for serosal, dermal and immunologic systems; 1 point for constitutional and hematological. The points were assigned if the 
descriptor is present at the time of the patient visit or within the preceding 10 days [1,12]. SLEDAI score = Sum of score points of 24 descriptors 
with minimum score = 0 and maximum score = 105. SLEDAI score grading: no, mild, moderate, and severe activities. 
  
Measuring the quality of life using SF-36 Health Survey questionnaire 
  
The Arabic [9] and the English [13] versions were used. The questionnaire included eight subscales (physical and social functioning, role limitations 
due to physical and emotional problems, mental health, energy/vitality, pain and general health perception) that can be summarized into two 
component scores; physical and mental component summary score. 
  
Laboratory investigations 
  
Laboratory investigation included complete blood picture and urine analysis. Kidney function tests, anti-nuclear antibodies (ANA), and anti-ds DNA 
antibodies (ELISA) were also performed. 
  
Pathological reports of kidney Biopsy 
  
Previous kidney biopsies were reviewed for all patients to estimate renal involvement and to determine the extent and severity of renal disease. 
Reports of biopsies were taken to be correlated with QoL of the patients. According to International Society of Nephrology – Renal Pathology 
Society Classification of Lupus Nephritis (2003), patients were classified into 6 classes: class I (minimal), class II (mesangial), class III (focal), class 
IV (diffuse), class V (membranous), and class VI (advanced sclerosis) [14,15]. 
   
Ethical consideration  
  
Informed consent was obtained from all the adults. The aim and the value of the work were explained in a simplified manner for them. There was 
no harm inflicted on them. On the contrary, all had benefited from follow-up and the final results of the study. The study was approved by the 
ethical committee of faculty of medicine, Suez Canal University. 
  
 Statistical Analysis 
  
The data were analyzed using parametric tests and presented in terms of mean, standard deviation (SD) of the mean and percentages. Statistical 
analysis was done using SPSS Ver. 11. Student-t, correlation coefficient, and Chi-square tests were used to evaluate the results. P value was set at 
<0.05 for statistically significant results and <0.0001 for highly significant results. 
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Results 
 
Out of 59 SLE patients, 56 were females (94.9%) and 3 patients (5.1%) were males. The age ranged from 16 to 42 years with a mean of 
28.6±6.6  years.  The  mean  disease  duration  was  5.6±3.4  years.  There  were  no  differences  between  cases  and  controls  for  demographic 
characteristic items (Table 1). 
  
For clinical and biochemical findings (Table 2), malar rash was presented in 91.5% of the patients, photosensitivity was presented in 83.1% and 
discoid rash was presented in 20.3%. Eighty five percent (85%) of the patients were presented with mucosal ulcers. Arthritis was present in 
52.5%  of  the  SLE  patients,  while  serositis  (cardiopulmonary  involvements)  was  present  in  44.1%  of  them.  10.2%  of  the  patients  had  had 
persistent proteinuria >0.5 grams/day or greater than 3+, 23.7% had cellular casts, and 54.2% had both proteinuria and urinary casts. About 51% 
of the patients had anemia, 55.9% had leucopenia and 33.9% had thrombocytopenia. 73% had elevated DNA and 6.8% had positive both anti-
DNA and anti-phospholipids Abs. 
 
According to SLEDAI score 51% of the SLE population in our study had mild activity and 27.2% had moderate to severe activity. No activity was 
present in 13%, while 16% had from moderate to severe activity. 
Regarding renal pathology classification of lupus nephritis, 12% of the patients had class I, 5.1% had class II, 57.6% had class III, 20.3% class IV 
and 5.1% had class V.  
Table 3 shows the main domains of QoL measured by SF-36 in SLE patients compared to control. All domains of SF-36 including general health, 
physical functions, physical limitations, energy/fatigue, emotional well-being, pain, social functions, and health changes were lower in the SLE 
patients compared with control except emotional limitations.  
Table 4 shows that all domains of SF-36 including general health, physical functions, physical limitations, emotional limitations, energy/fatigue, 
emotional well-being, pain, social functions, and health changes were negatively correlated with grades of disease activity as detected by SLEDAI. 
Table 5 shows the mean score of each domains of QoL measured by SF-36 according to renal pathology classification of lupus nephritis in SLE 
patients. All domains of SF-36 including general health, emotional limitations, physical limitations, energy/fatigue, emotional well-being, pain, social 
functions, and health changes were lower in class IV-V the SLE patients compared with other classes except physical functions.  
Table 6 shows the correlation between QoL score measured by SF-36 and activity score measured by SLEDAI in SLE patients. The correlation was 
assessed through Pearson correlation. There are significant correlations between general health, pain and social functions domains in QoL score 
and activity score measured by SLEDAI in SLE patients. 
 
 
Discussion 
  
In the evaluation of patients with SLE it is important to measure not only disease activity (which is potentially reversible with treatment) and 
damage (which is permanent and can be due to the disease or treatment) but also the patients’ perspective. This is because the disease is likely to 
have a significant impact on the physical, social and psychological aspects of the patient health and QoL [16].  
  
The  present  clinical  and  biochemical  data  had  revealed  that,  mucocutaneous  and  hematological  manifestations  were  present  in  most  of  the 
patients, while arthralgia was present in half of them. Many variations were seen in other studies. Ch et al studied 1082 SLE patients; 70% of the 
patients were characterized predominantly by mucocutaneous manifestations [17]. Sultan et al reported, out of 305 SLE patients, 2.5% only had 
hematological disorders [18]. In the cohort study of Alarcon et al., the first ACR criteria fulfilled were arthritis (34.5%) and photosensitivity Page number not for citation purposes  5 
(18.2%) [19]. In the Sultanate of Oman, Abdwani et al followed 50 children with lupus; the initial manifestations were arthritis or arthralgia (76%), 
cutaneous (70%), hematological (68%), and renal (64%) [20]. Additionally, Nazarinia et al found that out of 410 patients in Iran, 78% had 
hematological disorders and 38% had serositis [21]. Wallace and Tumlin, documented that 78% of SLE patients had anemia, and 30% had 
thrombocytopenia [22]. These variations may be due to different sample sizes, different patients' ages, variable diseases durations, unreported 
recent or mild cases, and seasonal, regional or racial variations. 
  
Traditionally, SLE is a disease with great impact on all aspects of health status. QoL is increasingly being recognized as an important aspect of 
chronic diseases. Its measurement has traditionally relied on the use of generic or disease-specific questionnaires. Generic questionnaires were 
developed for general use and may be used in a variety of diseases and populations. They allow for comparison with other groups and conditions 
and allow measurement of dysfunction for individuals experiencing more than one condition. Therefore, general health instruments have been 
shown to be valid for measuring QoL in SLE patients. In contrast, disease-specific questionnaires are designed to measure outcomes in a specific 
disease [23]. Only recently have disease-specific instruments been developed for use in SLE and these are not yet widely used [16]. 
  
In our study, we observed a progressive decrease in all SF-36 scores. These progressive changes in HRQoL could be due to several factors, such 
as SLE progression along the years, continuously coping with a chronic illness, and practical management items that may be required (frequent 
medical visits, laboratory examinations, etc.). Other possible explanations are that, most of our SLE patients were young adults females, and in 
ages at which physical, psychological and social stability had not yet been reached. The disease started at a crucial time in their lives when they 
were trying to establish relationships, start families and launch careers. As a result, patients experienced a wide range of physical, psychological 
and social problems. 
  
In addition, all domains of SF-36 including general health, physical functions, physical limitations, emotional limitations, energy/fatigue, emotional 
well-being, pain, social functions, and health changes were correlated with disease activity as detected by SLEDAI. 
  
Abu-Shakra M et al. found similar results. SF-36 scores were correlated with BILAG and SLEDAI scores, suggesting divergent construct validity of 
the SF-36 meaning it offered an independent assessment of the impact of SLE [24]. Also, Thumboo et al. reported that improvements in SF-36 
scores  correlate  with  decreases  in  disease  activity  and  damage.  Decrements  in  SF-36  scores  reflect  end  stage  renal  disease  and 
immunosuppressive use [25]. Various degrees of correlation between SLE disease activity and HR QoL were documented by some authors. In a 
cross-sectional analysis, Fortin PR et al. found that SLAM-R, correlated with most subscales of the SF-36. In a longitudinal analysis, both disease 
activity instruments (SLAM-R and SLEDAI) were associated with changes in the SF-36 [26]. Sutcliffe N et al. found that higher disease activity 
correlated with worse physical and emotional function, pain, and general health [7].  
  
Khanna et al. used the World Health Organization Quality of Life-Bref (WHOQoL-Bref) to evaluate the relationship between disease activity and 
health status in the Indian subcontinent. The WHOQoL-Bref includes an environment domain, which the authors wanted to capture. They found 
that physical and psychological QoL are impaired with active lupus, whereas social and environmental QoL do not correlate with disease activity 
[27]. Simone et al reported that patients with SLE and active renal disease concurrently experience a slightly poorer QoL than those without renal 
disease, especially in the physical domains [28]. Lai et al found that low-grade inflammation as reflected by low serum albumin and hemoglobin 
concentrations were associated with impaired HRQOL in patients with SLE, independent of other socio-demographic and clinical variables [29]. 
Study by Strand et al showed  that, the impact of SLE was evident - with decrements in HRQoL similar  to  those reported by patients with 
inflammatory arthritis, chronic congestive heart failure and post myocardial infarction despite differing disease activity and baseline disease [30]. 
  
To evaluate a cross-country comparison, Panopalis et al. (2005) evaluated the Short Form-36 General Health Survey (SF-36) scores done annually 
over 4 years in 231 patients from Canada, 269 from the United States, and 215 from the United Kingdom. They found that the physical and mental 
well-being components did not differ significantly between countries [31]. Whether the equivocal results on the relationship with disease activity 
and quality of life measures will be resolved with more uniform use of activity and health status indices remains to be seen. Larger studies 
including cohorts from diverse geographic regions are also needed for comparisons to better understand lupus variability. Page number not for citation purposes  6 
In addition, we reported that the QoL of SLE patients as measured by SF-36 was poorer than healthy control in all domains except emotional 
limitations. Both physical and mental component summary scores of the SF-36 were reduced in our studied patients compared with controls. In 
SLE great variability in all the subscales was observed. Significant correlations between physical and mental components and different subscales 
were observed in patients but not in controls. In SLE, HRQoL tended to worsen with age. Higher disease activity and damage were associated with 
significantly lower HRQoL and worsening of SLE leads to a further decline. The same observations were detected by Rinaldi et al. They examined 
HRQoL in Italian patients with SLE and compared it with that of healthy people and investigated relationships among different dimensions and 
subscales of a generic health status measure [32]. They used SF-36 as we do and it was applied in a cohort of 126 consecutive SLE patients and 
96 healthy controls. Current results were also in agreement with other studies in different patients age groups [33,34]. 
 
 
Conclusion 
 
Most of SLE studied patients were characterized predominantly by mucocutaneous and hematological manifestations. The QoL of SLE patients with 
renal involvement as measured by SF-36 was poorer than healthy control in all domains except emotional limitations. There are significant negative 
correlations between general health, pain and social functions domains in QoL score and activity score measured by SLEDAI in SLE patients. 
Physicians should focus on QoL and how to improve it in relation to bio-psychosocial approach, (health education regarding the negative impact of 
disease activity on the patients is required). The results of quality of life studies help physicians understand and give better support to SLE patients 
beside rapid meticulous control of disease activity. Further researches on the factors affecting QoL in SLE patients, including drugs are required.  
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T able 1: The socio-demographic characteristics of case and control groups 
Item  Case Group (N=59)  Control Group (N=20)  X
2  P 
  N  %  N  %     
                  
Age             
16-29 years  25  42.80%  9  45% 
5.73  n.s 
30-42  34  57.60%  11  55% 
                  
Gender             
Male  3  5.10%  1  5% 
6.8  n.s 
Female  56  94.90%  19  95% 
             
Marital status             
Single  11  18.60%  3  15% 
4.7  n.s 
Married  41  69.50%  15  75% 
Widow  4  6.70%  1  5% 
Divorced  3  5.20%  1  5% 
             
Educational status             
Illiterate  2  3.40%  1  5% 
5.3  n.s 
Write & read  5  8.50%  2  10% 
Moderate  37  62.70%  11  55% 
High  15  25.40%  6  30% 
             
Occupational status             
Officers  21  35.60%  6  30% 
3.75  n.s 
Workers  12  20.40%  5  25% 
Housewives  12  20.40%  6  30% 
Students  4  6.70%  1  5% 
Others  10  16.90%  2  10% 
n.s: non-significant  
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Table 2: Clinical and laboratory findings in studied SLE population 
Items  No  % 
        
Mucocutanous manifestations       
Malar rash  54  91.5 
Discoid rash  12  20.3 
Photosensitivity   49  83.1 
Oral ulcers  50  84.7 
        
Arthritis  31  52.5 
        
Serositis (pleurisy, pericardium rub)   26  44.1 
        
Renal findings       
Non  7  11..9 
Persistent proteinuria >0.5 grams/day or greater than 3+  6  10.2 
Cellular casts  14  23.7 
Both   32  54.2 
        
Neuropsychiatric manifestations       
Non  41  69.5 
Seizures  10  16.9 
Psychosis  1  1.7 
Persistence unexplained headache  7  11.9 
        
Hematological manifestations       
No  3  5.1 
Anemia  30  50.8 
Leucopenia (<4000/mm)  33  55.9 
Lymphopenia (<1500/mm)  3  5.1 
Thrombocytopenia (<100.000/mm)  20  33.9 
Anti-DNA & anti-phospholipids Abs negative  12  20.3 
Anti-DNA Abs positive   43  72.9 
Anti-DNA & anti-phospholipids Abs positive  4  6.8 
ANA positive  59  100 
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Table 3: Main domains of QoL measured by SF-36 in SLE patients and controls 
 
  
SLE  Control    
 
Mean  SD  Mean  SD  p-value 
 
General health  44.8  11.8  64.2  16.6  <0.001   
Physical functions  55.5  20.1  71  25.1  <0.001   
Physical limitations  26.3  37.3  75  24.4  <0.001   
Emotion limitations  71.1  28.2  73.3  17.5  n.s   
Energy/fatigue  42.5  15.9  68  23.8  <0.001   
Emotion well-Being  36.9  15.4  59.2  24.1  <0.001 
 
Pain  39.2  28.2  64.5  13.2  <0.001 
 
Social functions  55.5  23.2  71  27.8  <0.001 
 
Health change  64.8  24.2  79  16.5  <0.001 
 
QoL: Quality of Life, SLE: Systemic Lupus erythematosus, SF: Short Form–36 health questionnaire   
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T able 4: The socio-demographic characteristics of case and control groups 
Item  Case Group (N=59)  Control Group (N=20)  X
2  P 
  N  %  N  %     
                    
Age             
16-29 years  25  42.80%  9  45% 
5.73  n.s 
30-42  34  57.60%  11  55% 
                    
Gender             
Male  3  5.10%  1  5% 
6.8  n.s 
Female  56  94.90%  19  95% 
             
Marital status             
Single  11  18.60%  3  15% 
4.7  n.s 
Married  41  69.50%  15  75% 
Widow  4  6.70%  1  5% 
Divorced  3  5.20%  1  5% 
             
Educational status             
Illiterate  2  3.40%  1  5% 
5.3  n.s 
Write & read  5  8.50%  2  10% 
Moderate  37  62.70%  11  55% 
High  15  25.40%  6  30% 
             
Occupational status             
Officers  21  35.60%  6  30% 
3.75  n.s 
Workers  12  20.40%  5  25% 
Housewives  12  20.40%  6  30% 
Students  4  6.70%  1  5% 
Others  10  16.90%  2  10% 
n.s: non-significant  
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Table 5: Mean score of each domains of QoL measured by SF-36 according to renal pathology 
classification of lupus nephritis in SLE patients 
Domains  Class I-II  Class III  Class IV-V  p-value 
General health  46.9±13.2  43.3±10.5  40.0±6.7  <0.001 
Physical functions  57.5±22.4  57.0±15.1  54.3±21.7  n.s 
Physical limitations  35.3±4.4  17.5±3.4  11.7±6.5  <0.001 
Emotion limitations  96.7±10.5  87.3±28.4  84.4±25.3  <0.001 
Energy/fatigue  46.2±6.7  38.3±4.0  36.0±3.5  <0.001 
Emotion well-Being  39.6±8.5  33.6±9.3  32.8±9.0  <0.001 
Pain  46.6±3.7  31.5±2.5  25.8±3.9  <0.001 
Social functions  59.0±22.1  51.9±27.3  50.2±20.5  <0.001 
Health change  69.1±26.9  60.0±20.7  57.5±16.9  <0.001 
QoL: Quality of Life, SLE: Systemic Lupus Erythematosus SF-36: SF: Short Form–36 health 
questionnaire 
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Table 6: Correlations between QoL score measured by SF-36 and activity score measured by SLEDAI in SLE patients 
Domains  Pearson Correlation Coefficient  p-value (2-tailed) 
General health  -0.279  0.033* 
Physical functions  0.164  0.214 
Physical limitations  -0.224  0.088 
Emotion limitations  -0.07  0.598 
Energy/fatigue  -0.165  0.211 
Emotion well-Being  -0.035  0.79 
Pain  -0.32  0.014* 
Social functions  -0.3  0.021* 
Health change  -0.23  0.08 
QoL: Quality of Life, SLEDAI: SLE disease activity index, SLE: Systemic Lupus Erythematosus SF-36: SF: Short Form–36 health 
questionnaire 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 